New generation adenoviral vectors improve gene transfer by coxsackie and adenoviral receptor-independent cell entry

Kidney International

Volumn 61, Issue SUPPL. 1, 2002, Pages

  Reynolds, Paul N ^a   Curiel, David T ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Adenoviral infection; Coxsackie virus; Gene transfer; Knob domain

Indexed keywords

ADENOVIRUS VECTOR; VIRUS DNA; VIRUS RECEPTOR;

CLINICAL TRIAL; CONFERENCE PAPER; COXSACKIE VIRUS; DNA MODIFICATION; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; VIROGENESIS; VIRUS INFECTION; VIRUS TRANSCRIPTION;

EID: 0036175762     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.0610s1024.x     Document Type: Conference Paper

References (72)

1. Update on adenovirus and its vectors
2. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis
3. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis
4. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: A phase I clinical trial
5. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis
6. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
7. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
8. Adenoviral-mediated suicide gene therapy for ovarian cancer
9. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): A phase I trial
10. In vivo gene transfer into injured carotid arteries: Optimization and evaluation of acute toxicity
11. Adenoviridae: The viruses and their replication
12. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5
13. HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses
14. The coxsackie virus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F
15. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment
16. Adenovirus enhancement of transferrin-polylysine-mediated gene delivery
17. Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia
18. Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor independent gene transfer
19. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism
20. Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma
21. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector
22. Modification of the genetic program of human alveolar macrophages by adenovirus vectors in vitro is feasible but inefficient, limited in part by the low level of expression of the coxsackie/adenovirus receptor
23. Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro
24. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures
25. Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines
26. Targeted gene delivery by tropism-modified adenoviral vectors
27. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor
28. Enhanced in vivo gene delivery utilizing tropism-modified adenovirus vectors
29. Targeting adenoviral infection with basic fibroblast growth factor enhances gene delivery to vascular endothelial and smooth muscle cells
30. Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: Evidence for reduced toxicity and enhanced antitumor activity in mice
31. Retargeting of adenoviral vectors to neurons using the Hc fragment of tetanus toxin
32. Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM
33. Maturation of dendritic cells accompanies high efficiency gene transfer by a CD40-targeted adenoviral vector
34. Targeting adenovirus
35. Targeted adenovirus-mediated gene delivery to T cells via CD3
36. FGF2-enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer
37. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model
38. A targetable injectable adenoviral vector for selective gene delivery to pulmonary endnthelium in vivo
39. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies
40. Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin
41. Targeting a recombinant adenovirus vector to HCC cells using a bifunctional Fab-antibody conjugate
42. The adenobody approach to viral targeting: Specific and enhanced adenoviral gene delivery
43. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells
44. Organ targeting in vivo using phage display peptide libraries
45. Modification of an adenoviral vector with biologically selected peptides: A novel strategy for gene delivery to cells of choice
46. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display
47. Molecular adaptors for vascular-targeted adenoviral gene delivery
48. Genetic targeting of adenoviral vectors
49. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins
50. Efficient adenoviral gene transfer to kidney cortical vasculature utilizing a fiber modified vector
51. Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution
52. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob
53. Alpha v integrins as receptors for tumor targeting by circulating ligands
54. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches
55. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency
56. Insertion of an RGD motif into the HI loop of adenovirus alters the transgene expression profile of the systemically administered vector
57. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection
58. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae
59. Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism
60. CAR binding ablation does not change biodistribution or toxicity of adenoviral vectors
61. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin
62. Recombinant adenovirus vectors with knobless fibers for targeted gene transfer
63. Genetic retargeting of adenovirus: Novel strategy employing "deknobbing" of the fiber
64. Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium
65. Midkine promoter-based edenoviral vector gene delivery for pediatric solid tumors
66. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers
67. Insulation of a conditionally expressed transgene in an adenoviral vector
68. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo
69. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration
70. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo
71. "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung
72. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies